Ketoglutaric Acid for Hair Regrowth - Quick Reference Sheet
evipedia.ai
← Back

Ketoglutaric Acid for Hair Regrowth

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Ketoglutaric acid is a substance the body makes while turning food into energy, also sold as a dietary supplement and promoted for hair regrowth. That case rests entirely on laboratory and animal work; no study in people has measured hair count, thickness or density on it. The only human-derived hair finding points toward more patchy autoimmune hair loss, not less. Biologically interesting, commercially promoted, clinically untested. (Full Review)

Protocol

Baseline standard protocol
1 g daily
Sustained-release calcium α-ketoglutarate, the dose and form used in the largest human trial. Sports-nutrition practice instead runs 3.6–6 g of the plain salt.
Best time of day
With the largest meal
Most often breakfast. No circadian data exist; the timing is driven by gastric tolerance and by calcium absorption, better in divided daytime doses.
Single versus split dosing
Single dose at 1 g
Above 2 g, splitting into two or three doses improves gastric tolerance and keeps any single calcium bolus under 500 mg.
Time to effect
Time to effect
Unknown for hair in humans
Mouse follicles entered growth within weeks, but the human cycle means any real change needs 6–12 months and standardised photography to detect.
Practical stop rule for hair use
Twelve months
With no human hair data, a fixed review point matched to two full follicle cycles is the only defensible way to avoid indefinite use without a signal.
Intended duration
Open-ended in aging-research use
The rationale is replacing an age-related decline. For hair specifically, no duration has been validated, so any horizon is arbitrary.

Benefits

Contraindications
  • Hypercalcaemia (albumin-corrected serum calcium above 10.5 mg/dL)
  • Untreated primary hyperparathyroidism
  • Calcium-containing kidney stones, or hypercalciuria (above 300 mg/24 h in men, 250 mg/24 h in women), for calcium-bound forms
  • Chronic kidney disease stage 4 or 5 (filtration below 30 mL/min/1.73 m²)
  • Active malignancy known to carry an IDH1 or IDH2 mutation
  • Granulomatous disease with dysregulated vitamin D activation (sarcoidosis, active tuberculosis)
  • Pregnancy and lactation
  • Mutant-enzyme inhibitors (ivosidenib, enasidenib, olutasidenib)
    •
Key Interactions
  • Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide)
  • Activated vitamin D analogues (calcitriol, alfacalcidol, paricalcitol)
  • Cardiac glycosides (digoxin)
  • Antibiotics, thyroid replacement and bisphosphonates (doxycycline, ciprofloxacin, levofloxacin, levothyroxine, alendronate)
  • Over-the-counter antacids and calcium supplements (calcium carbonate, calcium citrate)
  • Over-the-counter high-dose vitamin D (above 4,000 international units daily)
  • Arginine and citrulline
  • Glutamine and other keto-acid salts (creatine and ornithine α-ketoglutarate)
  • Iron and vitamin C (potentiating, not adverse)
  • Topical or oral minoxidil
    •

Risk & Side Effects

  • Low: Added calcium load from calcium-bound forms; gastrointestinal intolerance; palpitations and light-headedness with arginine-bound forms (conflicted); possible increase in patchy autoimmune hair loss risk (conflicted)
  • Speculative: Theoretical opposition to minoxidil's enzyme targets; substrate supply in mutant-enzyme tumours

Monitoring

Marker Target Why
Serum calcium (albumin-corrected) 9.0–9.8 mg/dL Detects the calcium load from calcium-bound forms
Parathyroid hormone, intact 15–35 pg/mL Confirms calcium regulation is intact before adding a calcium salt
25-hydroxyvitamin D 40–60 ng/mL Governs how much of the added calcium is absorbed
Estimated glomerular filtration rate Above 90 mL/min/1.73 m² Surplus is cleared renally; falling filtration concentrates the load
Ferritin 50–150 ng/mL Low iron independently sustains hair shedding and starves the target enzymes of their cofactor
Thyroid-stimulating hormone 0.5–2.5 mIU/L Thyroid dysfunction is the commonest reversible cause of diffuse shedding
High-sensitivity C-reactive protein Below 1.0 mg/L Tracks the inflammatory tone the compound is claimed to lower, and contextualises ferritin
Hair density (magnified scalp imaging, hairs/cm²) No established target; track change from the individual's own baseline The only direct readout of the claimed effect

Cadence: Baseline panel drawn fasting; safety panel repeated at 8–12 weeks, then every 6–12 months on stable dosing. Photography at 6 and 12 months. Starting a thiazide diuretic, a vitamin D analogue or digoxin brings the panel forward.

Qualitative Assessment

  • Shedding volume on a fixed weekly count, such as hairs collected after a standardised wash
  • Regrowth of short, pigmented hairs along the hairline and part, distinct from fine, colourless hair
  • Perceived hair calibre and the feel of ponytail thickness
  • Scalp comfort: itching, tenderness or flaking, which point to a different diagnosis
  • Gastrointestinal comfort at the chosen dose and form
  • Energy and exercise recovery, the domains where the compound has its firmest human data
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.